Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma : Juntendo University and Astellas Establish "Direct Reprogramming Regenerative Medicine Course" for Scientific Breakthroughs

10/01/2021 | 02:12am EST

TOKYO, October 1, 2021 - Juntendo University (President: Hajime Arai, M.D., Ph.D.) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that the parties have established, inside Juntendo University Graduate School of Medicine, a joint research course entitled, "Direct Reprogramming Regenerative Medicine Course" (Professor & Director, Diagnostics and Therapeutics of Interactable Diseases, Intractable Disease Research Center, Genome Medical Center: Yasushi Okazaki M.D., Ph.D., Specially Appointed Professor: Masahito Matsumoto, Ph.D.). The course will be retained for a term of three years from October 2021.

This joint research course aims to create a new modality that maximizes the therapeutic effect for diseases with high unmet medical needs, such as type 1 diabetes, by direct reprogramming using the K factor*1 . Itwill also conduct research to expand this modality to other diseases. Juntendo University Graduate School of Medicine will be acquiring the basic data including the study of the optimal combination of direct reprogramming factors that include the K factor, and Astellas will be conducting the applied research for disease treatment by gene therapy using this factor and selection of the optimal modality.

Direct reprogramming is a biology that directly converts the fate of cells without passing through the pluripotent state. The technology that enables direct reprogramming in vivo has attracted attention as a new regenerative medicine technology. Unlike conventional therapies, direct reprogramming not only removes unwanted cells or replenishes necessary cells; it also converts unnecessary cells into necessary cells. It is therefore expected to show high efficacy against intractable diseases that have been thought to be incurable.

Juntendo University and Astellas have been conducting joint research collaboration on the establishment of differentiation methods for therapeutic cells by direct reprogramming based on the agreement executed in 2018. This time, as part of this joint research collaboration, the two parties have established this joint research course to further strengthen the partnership and progressively conduct research on direct reprogramming as a new therapeutic paradigm.

Through this joint research course, Juntendo University and Astellas will take on the challenge of drug discovery based on direct reprogramming technology, with the aim of providing patients with new treatment options.

Click below for a copy of the full press release

Disclaimer

Astellas Pharma Inc. published this content on 01 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 October 2021 06:11:09 UTC.


ę Publicnow 2021
All news about ASTELLAS PHARMA INC.
01:23aJapanese shares end lower on Omicron worries, Fed's hawkish tilt
RE
12/01Japanese shares fall on Omicron, Fed worries
RE
12/01ASTELLAS PHARMA : to Present Research on FLT3 Mutation-Positive Acute Myeloid Leukemia &nd..
PU
11/30WE PUBLISHED A STORY : “Patient centricity at Astellas—all about action.&rdquo..
PU
11/30ASTELLAS PHARMA : Patient centricity at Astellas—all about action
PU
11/26ASTELLAS PHARMA : Annual Report 2021 is now available.
PU
11/25ASTELLAS PHARMA : Pivotal Phase 3 Trial for Pediatric Praziquantel Completes with Positive..
PU
11/19ASTELLAS PHARMA : ' Efforts Against the Spread of the Coronavirus Disease (COVID-19)
PU
11/14ASTELLAS PHARMA : and Pantherna Enter into Technology Evaluation Agreement for Research of..
PU
11/12PLAUSIBILITY AND UNDUE BURDEN : A New Look Insufficiency After FibroGen v Akebia
AQ
More news
Financials
Sales 2022 1 327 B 11 724 M 11 724 M
Net income 2022 183 B 1 616 M 1 616 M
Net cash 2022 380 B 3 356 M 3 356 M
P/E ratio 2022 17,7x
Yield 2022 2,85%
Capitalization 3 252 B 28 790 M 28 723 M
EV / Sales 2022 2,16x
EV / Sales 2023 1,90x
Nbr of Employees 15 455
Free-Float 98,9%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 1 755,00 JPY
Average target price 2 458,33 JPY
Spread / Average Target 40,1%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Naoki Okamura CFO, Representative Director & Vice President
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.10.10%28 790
JOHNSON & JOHNSON0.44%416 161
ROCHE HOLDING AG18.38%343 323
PFIZER, INC.48.55%306 912
NOVO NORDISK A/S66.91%247 444
ELI LILLY AND COMPANY47.55%225 859